Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
NIH NCI

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 27 April 2001:
Vol. 292. no. 5517, pp. 614 - 615
DOI: 10.1126/science.292.5517.614
Prev | Table of Contents | Next

News of the Week

DRUG PATENTS:
Universities, NIH Hear the Price Isn't Right on Essential Drugs

Eliot Marshall

The University of Minnesota is in the middle of an international debate over whether the public should get back some of the profits generated by biomedical research it has funded. A major driving force has been the cost and availability of AIDS drugs in developing countries--an issue on which advocates of limiting drug profits claimed a victory last week in South Africa. And the U.S. National Institutes of Health is being drawn reluctantly into the fray by a congressional directive to identify big moneymaking drugs derived from NIH-funded research.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)